UK markets open in 1 hour 48 minutes
  • NIKKEI 225

    26,539.06
    +242.20 (+0.92%)
     
  • HANG SENG

    26,732.34
    +62.59 (+0.23%)
     
  • CRUDE OIL

    45.90
    +0.19 (+0.42%)
     
  • GOLD FUTURES

    1,807.30
    +1.80 (+0.10%)
     
  • DOW

    29,872.47
    -173.77 (-0.58%)
     
  • BTC-GBP

    13,350.65
    -600.04 (-4.30%)
     
  • CMC Crypto 200

    348.85
    -21.67 (-5.85%)
     
  • ^IXIC

    12,094.40
    +57.62 (+0.48%)
     
  • ^FTAS

    3,607.81
    -25.54 (-0.70%)
     

CureVac says in talks with potential vaccine development partners

·1-min read
FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen
FILE PHOTO: Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen

FRANKFURT (Reuters) - CureVac <5CV.DE> is still in discussions with pharma majors to find a potential partner for its experimental COVID-19 vaccine, the German biotech firm's chief executive said on Thursday.

"The location of the partner does not play a role. We are looking for a partner who is best placed to support us," Chief Executive Franz-Werner Haas told a media briefing.

He said that a global infrastructure to monitor possible side effects after market launch was among the aspects to be addressed by a partner, but he added that CureVac may also outsource this task to a service provider.

Haas said the group was close to launching a Phase III trial with about 36,000 participants to find out whether its vaccine can prevent infections and that it plans to produce 300-400 million vaccine doses next year.

(Reporting by Ludwig Burger and Caroline Copley; Editing by Riham Alkousaa)